文献速递前列腺癌

尿液生物标志物组合在前列腺癌风险评估中的成本效果

Cost-Effectiveness of Urinary Biomarker Panel in Prostate Cancer Risk Assessment.
PubMed 文献 · J Urol · 2018-08-29

本研究用马尔可夫决策分析模型,模拟美国前列腺特异性抗原升高男性接受超声引导前列腺穿刺活检及先检测SelectMDx尿液生物标志物组合再决定活检的策略。结果显示,引入该生物标志物组合可使每例患者平均获得0.045个质量调整生命年(QALY)并节省1694美元,在广泛敏感性分析中占优。

要点

  • SelectMDx尿液生物标志物组合用于前列腺癌风险评估可改善健康结局并降低费用。
  • 模拟18年 horizon 下,该策略每例患者平均增加0.045 QALY、节省1694美元。
  • 该策略在广泛单因素敏感性分析中均优于当前标准。

核心结论

  • 常规使用SelectMDx尿液生物标志物组合指导活检决策可改善美国前列腺癌风险男性的健康结局并降低费用。

研究设计与样本

  • 研究采用马尔可夫决策分析模型,模拟美国前列腺特异性抗原升高男性接受超声引导前列腺活检及先检测生物标志物组合再活检的策略。
  • 主要结局为质量调整生命年(QALY),次要结局为Medicare支付方视角的医疗费用。

主要发现

  • 当前标准策略下每例患者预期平均QALY为10.796,18年 horizon 内费用为11060美元。
  • 引入尿液生物标志物组合后每例患者预期平均QALY为10.841,平均费用为9366美元。
  • 该策略平均每例患者增加0.045 QALY并节省1694美元。
  • extrapolate 至每年311879名接受活检男性,预计每年度队列增加14035 QALY并节省528323026美元。
  • 生物标志物组合策略在广泛敏感性分析中均优于当前标准。

临床怎么用

  • 在前列腺特异性抗原升高的美国男性中,可考虑先检测SelectMDx尿液生物标志物组合再决定是否活检,以优化风险评估价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: SelectMDx (MDxHealth®) is a panel of urinary biomarkers used in conjunction with traditional risk factors to individualize risk prediction for clinically significant prostate cancer. In this study we sought to characterize the effectiveness of SelectMDx in a population of American men with elevated prostate specific antigen. MATERIALS AND METHODS: We developed a Markov decision analytical model to simulate the chain of events and downstream outcomes associated with ultrasound guided prostate biopsy and a strategy in which the biomarker panel is implemented prior to biopsy. The primary outcome was health outcomes, measured in QALYs (quality-adjusted life years). The secondary outcome was health care costs from the Medicare payer perspective. Multiple 1-way sensitivity analyses were performed to characterize model robustness. RESULTS: The expected mean QALYs per patient under the current standard was 10.796 at a cost of $11,060 during an 18-year horizon. Incorporating the urinary biomarker panel resulted in an expected mean of 10.841 QALYs per patient and a mean cost of $9,366, representing an average of 0.045 QALYs gained at a cost savings of $1,694 per patient. When extrapolating these data to a conservative estimate of 311,879 men per year undergoing biopsy, one would expect that the biomarker panel would result in an incremental 14,035 QALYs gained at a cost savings of $528,323,026 in each yearly cohort. The biomarker panel strategy dominated the current standard across a wide range of sensitivity analyses. CONCLUSIONS: Routine use of the SelectMDx urinary biomarker panel to guide biopsy decision making improved health outcomes and lowered costs in American men at risk for prostate cancer. This strategy may optimize the value of prostate cancer risk assessment in an era of increasing financial accountability.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Govers TM, Caba L, Resnick MJ, et al. Cost-Effectiveness of Urinary Biomarker Panel in Prostate Cancer Risk Assessment. J Urol. 2018. PMID: 30012363. doi:10.1016/j.juro.2018.07.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。